Full Name

Hazel Hunt

Position

Chief Scientific Officer

Quote

"The Phase I study of CORT125134 was contracted out to Quotient Sciences, largely due to Quotient Sciences’ ability to integrate manufacturing and dosing on the same site. Dosing decisions could be made very rapidly as soon as data from the previous cohort was available - there was no need to define and manufacture all the doses up front - minimizing delay."

Company

Corcept Therapeutics